Therapeutic agent developed by Neil Bander, MD, Weill Cornell Urology Physician Scientist, shows promise in new trials to provide treatment for advanced prostate cancer.
PSMA radioligand therapy, developed at Weill Cornell Medicine, Department of Urology by Neil Bander, M.D. has been recently tested in a German clinical study using the therapeutic agent Lu-177 PSMA, with promising efficacy for treatment of metastatic castration resistant prostate cancer. Of patients that received at least two cycles of PSMA radioligand therapy monitored for at least 6 months, more than half showed partial remission. Additional highlights of this study include a dropping PSA level in the overwhelming majority of patients, reduction of metastases-associated pain, minimal short-term adverse side effects and undetectable long-term adverse side effects.
The study concludes that PSMA radioligand therapy is safe and effective for treatment of advanced prostate cancer. While the volume of patients that participated in the trial was relatively small, the results show great promise for clinical implementation and effective treatment of metastatic castration resistant prostate cancer in the coming years.
The full study text can be read on the Journal of Nuclear Medicine’s website: